The human kallikrein 10 promoter contains a functional retinoid response element

Biological Chemistry

Volumn 387, Issue 6, 2006, Pages 741-747

  Zeng, Musheng ^a,d   Zhang, Ying ^b   Bhat, Ishfaq ^b   Wazer, David E ^a   Band, Hamid ^b,c   Band, Vimla ^a,b,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Breast cancer; Kallikrein 10; RAR; Retinoic acid response element; RXR

Indexed keywords

KALLIKREIN; KALLIKREIN 10; RETINOIC ACID; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; BREAST CANCER; BREAST EPITHELIUM; CANCER INVASION; CANCER PATIENT; CELL IMMORTALIZATION; CONFERENCE PAPER; DNA RESPONSIVE ELEMENT; EPITHELIUM CELL; GEL MOBILITY SHIFT ASSAY; IMMUNOPRECIPITATION; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REPORTER GENE;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; NEOPLASMS; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; RETINOID X RECEPTORS; RETINOIDS;

EID: 33745660354     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2006.093     Document Type: Conference Paper

References (28)

1. Astrom, A., Pettersson, U., Chambon, P., and Voorhees, J.J. (1994). Retinoic acid induction of human cellular retinoic acid-binding protein-II gene transcription is mediated by retinoic acid receptor-retinoid X receptor heterodimers bound to one far upstream retinoic acid-responsive element with 5-base pair spacing. J. Biol. Chem. 269, 22334-22339.
2. Band, V., Zajchowski, D., Swisshelm, K., Trask, D., Kulesa, V., Cohen, C., Connolly, J., and Sager, R. (1990). Tumor progression in four mammary epithelial cell lines derived from the same patient. Cancer Res. 50, 7351-7357.
3. Borgono, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876-890.
4. Borgono, C.A., Michael, I.P., and Diamandis, E.P. (2004). Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2, 257-280.
5. Cleutjens, K.B., van der Korput, H.A., van Eekelen, C.C., van Rooij, H.C., Faber, P.W., and Trapman, J. (1997). An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 11, 148-161.
6. Coradini, D. and Daidone, M.G. (2004). Biomolecular prognostic factors in breast cancer. Curr. Opin. Obstet. Gynecol. 16, 49-55.
7. Dhar, S., Bhargava, R., Yunes, M., Li, B., Goyal, J., Naber, S.P., Wazer, D.E., and Band, V. (2001). Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer. Clin. Cancer Res. 7, 3393-3398.
8. Dimri, G., Band, H., and Band, V. (2005). Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res. 7, 171-179.
9. Goyal, J., Smith, K.M., Cowan, J.M., Wazer, D.E., Lee, S.W., and Band, V. (1998). The role for NES1 serine protease as a novel tumor suppressor. Cancer Res. 58, 4782-4786.
10. Lewis, B.A. and Reinberg, D. (2003). The mediator coactivator complex: functional and physical roles in transcriptional regulation. J. Cell Sci. 116, 3667-3675.
11. Li, B., Goyal, J., Dhar, S., Dimri, G., Evron, E., Sukumar, S., Wazer, D.E., and Band, V. (2001). CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res. 61, 8014-8021.
12. Liu, X.L., Wazer, D.E., Watanabe, K., and Band, V. (1996). Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 56, 3371-3379.
13. Luo, L.Y., Grass, L., and Diamandis, E.P. (2003). Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin. Chim. Acta 337, 115-126.
14. Magklara, A., Brown, T.J., and Diamandis, E.P. (2002). Characterization of androgen receptor and nuclear receptor co-regulator expression in human breast cancer cell lines exhibiting differential regulation of kallikreins 2 and 3. Int. J. Cancer 100, 507-514.
15. Meng, G., Zhao, Y., Nag, A., Zeng, M., Dimri, G., Gao, Q., Wazer, D.E., Kumar, R., Band, H., and Band, V. (2004). Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. J. Biol. Chem. 279, 54230-54240.
16. Pelzer, A.E., Volgger, H., Bektic, J., Berger, A.P., Rehder, P., Bartsch, G., and Horninger, W. (2005). The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels. BJU Int. 96, 995-998.
17. Ramharack, R., Wyborski, R.J., and Spahr, M.A. (1998). The apolipoprotein(a) promoter contains a retinoid response element. Biochem. Biophys. Res. Commun. 245, 194-197.
18. Rastinejad, F. (2001). Retinoid X receptor and its partners in the nuclear receptor family. Curr. Opin. Struct. Biol. 11, 33-38.
19. Sidiropoulos, M., Pampalakis, G., Sotiropoulou, G., Katsaros, D., and Diamandis, E.P. (2005). Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol. 26, 324-336.
20. Stewart, A.J., Scher, H.I., Chen, M.H., McLeod, D.G., Carroll, P.R., Moul, J.W., and D'Amico, A.V. (2005). Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J. Clin. Oncol. 23, 6556-6560.
21. Wazer, D.E., Chu, Q., Liu, X.L., Gao, Q., Safaii, H., and Band, V. (1994). Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. Mol. Cell. Biol. 14, 2468-2478.
22. Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., Savagner, P., Gitelman, I., Richardson, A., and Weinberg, R.A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939.
23. Yousef, G.M. and Diamandis, E.P. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204.
24. Yousef, G.M., Scorilas, A., Kyriakopoulou, L.G., Rendl, L., Diamandis, M., Ponzone, R., Biglia, N., Giai, M., Roagna, R., Sismondi, P., and Diamandis, E.P. (2002). Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. Clin. Chem. 48, 1241-1250.
25. Yousef, G.M., Scorilas, A., Katsaros, D., Fracchioli, S., Iskander, L., Borgono, C., Rigault de la Longrais, I.A., Puopolo, M., Massobrio, M., and Diamandis, E.P. (2003). Prognostic value of the human kallikrein gene 15 expression in ovarian cancer. J. Clin. Oncol. 21, 3119-3126.
26. Yousef, G.M., Obiezu, C.V., Luo, L.Y., Magklara, A., Borgono, C.A., Kishi, T., Memari, N., Michael, P., Sidiropoulos, M., Kurlender, L., et al. (2005). Human tissue kallikreins: from gene structure to function and clinical applications. Adv. Clin. Chem. 39, 11-79.
27. Yunes, M.J., Neuschatz, A.C., Bornstein, L.E., Naber, S.P., Band, V., and Wazer, D.E. (2003). Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. Int. J. Radiat. Oncol. Biol. Phys. 56, 653-657.
28. Zeng, M., Kumar, A., Meng, G., Gao, Q., Dimri, G., Wazer, D., Band, H., and Band, V. (2002). Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J. Biol. Chem. 277, 45611-45618.